TREKing toward new antidepressants

Nature Neuroscience

Volumn 9, Issue 9, 2006, Pages 1081-1083

  Gordon, Joshua A ^a,b   Hen, Rene ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEW DRUG; POTASSIUM CHANNEL; POTASSIUM CHANNEL TREK 1; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

BEHAVIOR; CELL ACTIVITY; DEPRESSION; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; HIPPOCAMPUS; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BLOCKING; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SHORT SURVEY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSIVE DISORDER; FLUOXETINE; GENE DELETION; MICE; MICE, KNOCKOUT; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PYRAMIDAL CELLS;

EID: 33748123045     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn0906-1081     Document Type: Short Survey

References (8)

1. Heurteaux, C. et al. Nat. Neurosci. 9, 1134-1141 (2006).
2. Duman, R.S., Nakagawa, S. & Malberg, J. Neuropsychopharmacology 25, 836-844 (2001).
3. Santarelli, L. et al. Science 301, 805-809 (2003).
4. Urani, A., Chourbaji, S. & Gass, P. Neurosci. Biobehav. Rev. 29, 805-828 (2005).
5. Haddjeri, N., Blier, P. & de Montigny, C. J. Neurosci. 18, 10150-10156 (1998).
6. Lesage, F. & Lazdunski, M. Am. J. Physiol. Renal Physiol. 279, F793-F801 (2000).
7. Fink, M. et al. EMBO J. 15, 6854-6862 (1996).
8. Kennard, L.E. et al. Br. J. Pharmacol. 144, 821-829 (2005).